Entrada Therapeutics: A Complicated Tale [Seeking Alpha]
Entrada Therapeutics, Inc. (TRDA)
Company Research
Source: Seeking Alpha
The company's EEV platform aims to target malady-inducing dysfunction inside cells with high proficiency, potentially revolutionizing treatment across various diseases. Despite ongoing FDA issues, analysts remain optimistic about Entrada's prospects, with a well-padded balance sheet and potential for future collaborations. An analysis around Entrada Therapeutics stock follows in the paragraphs below. Shares of intracellular treatment concern Entrada Therapeutics, Inc. ( NASDAQ: TRDA are down significantly from their all-time high as a protracted hold on the two IND applications has tempered enthusiasm. Its two clinical assets (one out-licensed) are undergoing early-stage studies in the UK Recommended For You Recommended For You About TRDA Stock More on TRDA Related Stocks Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
TRDA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRDA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRDA alerts
High impacting Entrada Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TRDA
News
- Entrada Therapeutics, Inc. (NASDAQ: TRDA) had its price target lowered by analysts at HC Wainwright from $20.00 to $18.00. They now have a "buy" rating on the stock.MarketBeat
- Entrada Therapeutics Announces $100 Million Registered Direct Offering [Yahoo! Finance]Yahoo! Finance
- Entrada Therapeutics Announces $100 Million Registered Direct OfferingGlobeNewswire
- Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy [Yahoo! Finance]Yahoo! Finance
- Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular DystrophyGlobeNewswire
TRDA
Earnings
- 5/7/24 - Beat
TRDA
Sec Filings
- 6/24/24 - Form 8-K
- 6/24/24 - Form 424B5
- 6/24/24 - Form 8-K
- TRDA's page on the SEC website